Momma Kliff used to tell us all the time don’t fight ignorance it’s a losing battle that you cannot win. We thought about Mom a lot yesterday while watching shares of Tandem tack on 12%+ closing at almost $99. All this from their announcement that they have finalized their deal with Abbott to eventually integrate Abbott’s Libre platform into Tandem’s insulin pump platform. Which will be a neat trick since the recently approved Libre2 CANNOT be used with any automated insulin delivery system or one that has low glucose suspend. But what the heck why bother . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.